2025年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20250731

中华皮肤科杂志 ›› 2026, e20250731.doi: 10.35541/cjd.20250731

• 综述 • 上一篇

2025年系统性红斑狼疮研究新进展

罗帅寒天¹ 龙海¹ 陆前进^2，3

¹中南大学湘雅二医院皮肤性病科，长沙 410011；²中国医学科学院北京协和医学院，皮肤病医院皮肤科，南京 210042；³中国医学科学院免疫性皮肤病基础与转化研究重点实验室，南京 210042

收稿日期:2025-12-29 修回日期:2026-06-26 发布日期:2026-08-10
通讯作者: 陆前进 E-mail:qianlu5860@pumcderm.cams.cn
基金资助:
国家自然科学基金（82273540）；湖南省科技创新领军人才（拔尖）项目（2023RC1031）；湖南省自然科学基金（2023JJ10089）

Research advances in systemic lupus erythematosus in 2025

Luo Shuaihantian¹, Long Hai¹, Lu Qianjin^2,3

¹Department of Dermatology and Venereology, the Second Xiangya Hospital of Central South University, Changsha 410011, China; ²Department of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Nanjing 210042, China; ³Key Laboratory of Immunological Dermatology and Translational Research, Chinese Academy of Medical Sciences, Nanjing 210042, China

Received:2025-12-29 Revised:2026-06-26 Published:2026-08-10
Contact: Lu Qianjin E-mail:qianlu5860@pumcderm.cams.cn
Supported by:
National Natural Science Foundation of China （82273540）; Hunan Provincial Program for Leading Talents in Scientific and Technological Innovation （Top-notch Category）（2023RC1031）; Natural Science Foundation of Hunan Province （2023JJ10089）

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮是一种好发于年轻女性，并可累及多个器官系统的复杂自身免疫性疾病。2025年在系统性红斑狼疮的发病机制、诊断和评估、治疗等方面取得了一系列研究进展，本文就主要代表性成果进行综述。

关键词: 红斑狼疮, 系统性, 发病机制, 诊断, 治疗, 研究进展

Abstract: 【Abstract】 Systemic lupus erythematosus （SLE） is a complex autoimmune disease primarily affecting young women and can involve multiple organs and systems. In 2025, significant advancements have been made in SLE research, particularly in its pathogenesis, diagnosis and assessment, and treatment. This article reviews the key representative findings.

Key words: Lupus erythematosus, systemic, Pathogenesis, Diagnosis, Therapy, Research advances

罗帅寒天龙海陆前进. 2025年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2026,e20250731. doi:10.35541/cjd.20250731

Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2025[J]. Chinese Journal of Dermatology,2026,e20250731. doi:10.35541/cjd.20250731

参考文献 23

［1］	Wang Q, Zhu H, Sun X, et al. Loss⁃of⁃function mutations in PLD4 lead to systemic lupus erythematosus［J］. Nature, 2025,647（8089）:498⁃505. DOI: 10.1038/s41586⁃025⁃09513⁃x.
［2］	Tumurkhuu G, Perri G, Moore R, et al. Loss of tripartite motif⁃containing protein 21 and UVB⁃induced systemic inflammation by regulating DNA⁃sensing pathways［J］. Arthritis Rheumatol, 2026,78（1）:172⁃183. DOI: 10.1002/art.43273.
［3］	Zeng Q, Li L, Li X, et al. The m6A demethylase FTO links TLR7 to mitochondrial oxidation driving age⁃associated B cell formation in systemic lupus erythematosus［J］. Sci Transl Med, 2025,17（823）:eadu6015. DOI: 10.1126/scitranslmed.adu6015.
［4］	Yuen E, Fried J, Nguyen SA, et al. Hearing loss in patients with systemic lupus erythematosus: a systematic review and meta⁃analysis［J］. Lupus, 2021,30（6）:937⁃945. DOI: 10.1177/09612 03321997919.
［5］	Zhao Z, Li A, Zhu Y, et al. Blood⁃labyrinth barrier damage mediated by granzymes from cytotoxic lymphocytes results in hearing loss in systemic lupus erythematosus［J］. Proc Natl Acad Sci U S A, 2025,122（33）:e2423240122. DOI: 10.1073/pnas. 2423240122.
［6］	Wang J, Zheng A, Liu N, et al. Integrative spatial multiomics analysis reveals regulatory mechanisms of VCAM1+ proximal tubule cells in lupus nephritis［J］. Ann Rheum Dis, 2025,84（12）:2021⁃2033. DOI: 10.1016/j.ard.2025.08.015.
［7］	Nikolopoulos D, Sentis G, Kitsios I, et al. Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus［J］. Ann Rheum Dis, 2025,84（8）:1342⁃1353. DOI: 10.1016/j.ard.2025.04.006.
［8］	Li T, Lin S, Guan Z, et al. A deep learning system for detecting systemic lupus erythematosus from retinal images［J］. Cell Rep Med, 2025,6（7）:102203. DOI: 10.1016/j.xcrm.2025.102203.
［9］	Zaslavsky ME, Craig E, Michuda JK, et al. Disease diagnostics using machine learning of B cell and T cell receptor sequences［J］. Science, 2025,387（6736）:eadp2407. DOI: 10.1126/science.adp2407.
［10］	Azoulay LD, Kachenoura N, Boussouar S, et al. Diagnostic and prognostic value of quantitative cardiac magnetic resonance imaging biomarkers in systemic lupus erythematosus: a systematic review and meta⁃analysis［J］. Eur Radiol, 2025,35（7）:3858⁃3870. DOI: 10.1007/s00330⁃024⁃11282⁃6.
［11］	国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组, 中华医学会风湿病学分会. 中国系统性红斑狼疮诊疗指南（2025版）［J］. 中华医学杂志, 2025,105（23）:1879⁃1906. DOI: 10.3760/cma.j.cn112137⁃20250228⁃00479.
［12］	Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology （ACR） guideline for the treatment of systemic lupus erythematosus［J］. Arthritis Rheumatol, 2026,78（7）:1361⁃1386.
［13］	van Vollenhoven RF, Wang L, Merrill JT, et al. A phase 3 trial of telitacicept for systemic lupus erythematosus［J］. N Engl J Med, 2025,393（15）:1475⁃1485. DOI: 10.1056/NEJMoa2414719.
［14］	Manzi S, Bruce IN, Morand EF, et al. Efficacy and safety of subcutaneous anifrolumab in systemic lupus erythematosus: a randomized, phase 3 study［J］. Arthritis Rheumatol, 2026,78（6）:1258⁃1267. DOI: 10.1002/art.70041.
［15］	Wang Q, Xiao ZX, Zheng X, et al. In vivo CD19 CAR T⁃cell therapy for refractory systemic lupus erythematosus［J］. N Engl J Med, 2025,393（15）:1542⁃1544. DOI: 10.1056/NEJMc2509522.
［16］	Wang X, Zhang Y, Wang H, et al. Allogeneic CD19⁃targeting T cells for treatment⁃refractory systemic lupus erythematosus: a phase 1 trial［J］. Nat Med, 2025,31（11）:3713⁃3724. DOI: 10. 1038/s41591⁃025⁃03899⁃x.
［17］	Feng J, Huo D, Hong R, et al. Co⁃infusion of CD19⁃targeting and BCMA⁃targeting CAR⁃T cells for treatment⁃refractory systemic lupus erythematosus: a phase 1 trial［J］. Nat Med, 2025,31（11）:3725⁃3736. DOI: 10.1038/s41591⁃025⁃03937⁃8.
［18］	Gao J, Li M, Sun M, et al. Efficacy and safety of allogeneic CD19 CAR NK⁃cell therapy in systemic lupus erythematosus: a case series in China［J］. Lancet, 2026,406（10522）:2968⁃2979. DOI: 10.1016/S0140⁃6736（25）01671⁃X.
［19］	Liang Z, Xie H, Mao M, et al. Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate［J］. J Autoimmun, 2025,157:103497. DOI: 10.1016/j.jaut.2025.103497.
［20］	Wu K, DeVita RJ, Pan ZQ. Modulation of Cullin⁃RING E3 ubiquitin ligase⁃dependent ubiquitination by small molecule compounds［J］. J Biol Chem, 2024,300（3）:105752. DOI: 10.1016/j.jbc.2024.105752.
［21］	Wang Y, Levin R, Martinez L, et al. POS0057 KPG⁃818, a novel cereblon modulator in patients with systemic lupus erythematosus: results of a randomize, double⁃blind, placebo⁃controlled, phase 2a study［J］. Ann Rheum Dis, 2024, 83（Supplement 1）: 329⁃330. DOI: 10.1136/annrheumdis⁃2024⁃eular.2675.
［22］	Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis［J］. N Engl J Med, 2025,392（15）:1471⁃1483. DOI: 10.1056/NEJMoa2410965.
［23］	Li W, Kolios A, Pan W, et al. Gluconolactone restores immune regulation and alleviates skin inflammation in lupus⁃prone mice and in patients with cutaneous lupus［J］. Sci Transl Med, 2025,17（786）:eadp4447. DOI: 10.1126/scitranslmed.adp4447.

[1]	《西罗莫司治疗卡波西样血管内皮瘤中国专家共识（版）》制订专家组. 西罗莫司治疗卡波西样血管内皮瘤中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 728-737.
[2]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 中国皮肤鳞状细胞癌诊疗指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 703-716.
[3]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. [开放获取] 脓疱型银屑病诊疗中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 717-727.
[4]	李燕红姜琨吴卓璇章建兰方美珍刘姝婷王琳琳胡磊周小勇陈柳青陈金波. 程序性死亡受体1抑制剂相关皮肤不良反应18例临床资料分析[J]. 中华皮肤科杂志, 2026, 59(8): 783-787.
[5]	何庆张涛王秀丽高兴华陈洪铎柳敏齐瑞群. 光线性角化病恶性进展相关生物标志物的研究进展[J]. 中华皮肤科杂志, 2026, 59(7): 687-690.
[6]	魏瑾闫会文张建中伦文辉. 司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察[J]. 中华皮肤科杂志, 2026, 59(7): 671-674.
[7]	王琳琳曹立娟陈柳青李东升胡燕燕. 海姆泊芬光动力疗法治疗四肢鲜红斑痣疗效观察及安全性回顾分析[J]. 中华皮肤科杂志, 2026, 59(7): 637-644.
[8]	刘怿菲金炫沃刘鹏月张希萌吴严. 点阵CO2激光联合A型肉毒毒素外用治疗面部毛孔粗大的半脸自身对照临床试验[J]. 中华皮肤科杂志, 2026, 59(7): 645-653.
[9]	张国龙赵子君. 氨基酮戊酸光动力疗法治疗皮肤鳞状细胞癌的现状、挑战和思考[J]. 中华皮肤科杂志, 2026, 59(7): 626-631.
[10]	中国研究型医院学会皮肤科学专业委员会中国医师协会皮肤科医师分会. [开放获取] 窄谱中波紫外线光疗皮肤科临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 595-610.
[11]	中华医学会皮肤性病学分会光动力治疗研究协作组中国康复医学会皮肤病康复专业委员会及光动力治疗与康复专业委员会中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法治疗尖锐湿疣的临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 611-618.
[12]	中华医学会皮肤性病学分会儿童皮肤病学组中华医学会儿科学分会皮肤病学组中国康复医学会皮肤病康复专业委员会儿童学组中国康复医学会皮肤病康复专业委员会特应性皮炎学组中国医师协会皮肤科医师分会儿童皮肤病学组中国医师协会儿科学分会皮肤病学组. [开放获取] 中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(6): 487-504.
[13]	杜欣冉王歆荷李思宇陈谟安袁少杰鄢然程淋燕郭婉军王怡李福伦. [开放获取] 特应性皮炎血虚风燥证诊断量表的构建及评价研究[J]. 中华皮肤科杂志, 2026, 59(6): 540-546.
[14]	李巍姚煦. 中国特应性皮炎的研究现状与展望[J]. 中华皮肤科杂志, 2026, 59(6): 505-511.
[15]	田静宋志强. 胶带剥离法在特应性皮炎生物标志物检测中的研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 578-581.

2025年系统性红斑狼疮研究新进展

Research advances in systemic lupus erythematosus in 2025

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 23

相关文章 15

Metrics

本文评价

推荐阅读 0